X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10702) 10702
Book Review (1569) 1569
Publication (611) 611
Newsletter (70) 70
Magazine Article (52) 52
Conference Proceeding (17) 17
Book Chapter (13) 13
Newspaper Article (12) 12
Transcript (8) 8
Dissertation (7) 7
Book / eBook (6) 6
Trade Publication Article (6) 6
Government Document (2) 2
Data Set (1) 1
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9379) 9379
humans (8756) 8756
male (5227) 5227
sulfonamides - adverse effects (4941) 4941
female (4560) 4560
sulfonamides - therapeutic use (4200) 4200
middle aged (3503) 3503
adult (2818) 2818
aged (2709) 2709
sulfonamides - administration & dosage (2456) 2456
animals (2122) 2122
sulfonamides - pharmacology (1920) 1920
pharmacology & pharmacy (1832) 1832
treatment outcome (1794) 1794
celecoxib (1610) 1610
sulfonamides (1292) 1292
abridged index medicus (1263) 1263
drug therapy, combination (1037) 1037
double-blind method (946) 946
oncology (900) 900
drug therapy (888) 888
analysis (863) 863
aged, 80 and over (862) 862
dose-response relationship, drug (848) 848
anti-inflammatory agents, non-steroidal - adverse effects (791) 791
pyrimidines - therapeutic use (787) 787
sulfonamides - pharmacokinetics (778) 778
care and treatment (762) 762
rosuvastatin calcium (744) 744
medicine, general & internal (716) 716
adolescent (700) 700
rats (697) 697
therapy (674) 674
efficacy (660) 660
prospective studies (645) 645
pyrimidines - adverse effects (624) 624
medicine & public health (607) 607
time factors (606) 606
mice (603) 603
safety (595) 595
research (590) 590
cardiac & cardiovascular systems (587) 587
risk factors (586) 586
cancer (561) 561
pyrazoles (543) 543
nonsteroidal antiinflammatory drugs (542) 542
cyclooxygenase inhibitors - adverse effects (537) 537
administration, oral (521) 521
pyrazoles - adverse effects (516) 516
drug interactions (514) 514
pyrazoles - therapeutic use (497) 497
anti-inflammatory agents, non-steroidal - therapeutic use (490) 490
pharmacokinetics (488) 488
clinical trials (470) 470
double-blind (468) 468
indoles - adverse effects (468) 468
young adult (464) 464
health aspects (460) 460
drug administration schedule (450) 450
dosage and administration (445) 445
fluorobenzenes - therapeutic use (438) 438
clinical trials as topic (431) 431
retrospective studies (431) 431
pyrimidines - administration & dosage (422) 422
drugs (413) 413
antihypertensive agents - therapeutic use (411) 411
cyclooxygenase inhibitors - therapeutic use (410) 410
antineoplastic agents - adverse effects (407) 407
risk (394) 394
antineoplastic agents - therapeutic use (392) 392
urology & nephrology (386) 386
cox-2 inhibitors (385) 385
child (381) 381
internal medicine (375) 375
rosuvastatin (373) 373
follow-up studies (369) 369
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (367) 367
randomized controlled trials as topic (367) 367
ophthalmology (365) 365
antibiotics (363) 363
expression (362) 362
indoles - therapeutic use (362) 362
hypertension (358) 358
toxicology (355) 355
melanoma - drug therapy (353) 353
pharmacology/toxicology (353) 353
dermatology (352) 352
rheumatoid-arthritis (342) 342
trial (341) 341
cyclooxygenase 2 (340) 340
hiv infections - drug therapy (340) 340
sulfonamides - chemistry (338) 338
hypertension, pulmonary - drug therapy (336) 336
drug combinations (323) 323
melanoma (319) 319
cyclooxygenase 2 inhibitors (317) 317
surgery (314) 314
gastroenterology & hepatology (307) 307
environmental sciences (306) 306
pharmacology (304) 304
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9821) 9821
German (353) 353
French (206) 206
Spanish (89) 89
Italian (80) 80
Japanese (55) 55
Russian (53) 53
Chinese (28) 28
Norwegian (23) 23
Polish (23) 23
Swedish (22) 22
Dutch (21) 21
Czech (19) 19
Danish (12) 12
Hungarian (10) 10
Romanian (10) 10
Finnish (9) 9
Portuguese (8) 8
Serbian (7) 7
Hebrew (6) 6
Croatian (3) 3
Slovak (3) 3
Bulgarian (2) 2
Turkish (2) 2
Afrikaans (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2017, Volume 76, Issue Suppl 2, p. 279
BackgroundSalazosulfapyridine is non-antimicrobial sulfonamides, which is used as a synthetic disease modified anti-rheumatic-drug (DMARD) for rheumatoid... 
Autoantibodies | Psoriasis | Connective tissue diseases | Hypersensitivity | Liver | Rheumatic diseases | Trimethoprim | Arthritis | Eosinophilia | Fever | Risk factors | Trimethoprim-sulfamethoxazole | Sulfamethoxazole | Side effects | Systemic lupus erythematosus | Sulfonamides | Rheumatoid arthritis | Lymphadenitis | Neutropenia
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2015, Volume 29, Issue 1, pp. 61 - 68
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 13, pp. 1265 - 1267
Vemurafenib, a BRAF inhibitor, has been associated with a number of cutaneous adverse effects, mainly through the activation of MAP kinases. Pyogenic granuloma... 
MEDICINE, GENERAL & INTERNAL | BRAF | MELANOMA | INHIBITION | Drug Eruptions - etiology | Indoles - adverse effects | Skin Neoplasms - drug therapy | Granuloma, Pyogenic - chemically induced | Nose - pathology | Humans | Melanoma - drug therapy | Sulfonamides - adverse effects | Male | Aged | Granuloma, Pyogenic - pathology | Granuloma | Side effects | Metastasis | Mutation | Melanoma
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 22, pp. 2078 - 2087
In this trial, intravascular ultrasonography was used to compare the effects of atorvastatin versus rosuvastatin on regression of coronary atherosclerosis.... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | ATHEROSCLEROSIS | INTRAVASCULAR ULTRASOUND | RANDOMIZED CONTROLLED-TRIAL | AVERAGE CHOLESTEROL LEVELS | ROSUVASTATIN | ARTERY-DISEASE | ATORVASTATIN | Coronary Vessels - diagnostic imaging | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Ultrasonography, Interventional | Male | Heptanoic Acids - adverse effects | Coronary Artery Disease - pathology | Pyrroles - adverse effects | Cholesterol, LDL - blood | Female | Pyrroles - therapeutic use | Coronary Vessels - pathology | Double-Blind Method | Rosuvastatin Calcium | Coronary Artery Disease - drug therapy | Anticholesteremic Agents - adverse effects | Disease Progression | Atorvastatin Calcium | Coronary Artery Disease - diagnostic imaging | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Cholesterol, HDL - blood | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Drugs | Rosuvastatin | Dosage and administration | Product/Service Evaluations | Drug therapy | Atherosclerosis | Lipoproteins (low density) | Clinical trials | Cardiovascular disease | Patients | Cholesterol | Studies | Side effects | Ultrasonic imaging | Arteriosclerosis | Ultrasonography | Atorvastatin | Heart diseases | Lipoproteins (high density) | Statins | Index Medicus | Abridged Index Medicus
Journal Article
14.